Evidence map›Paper›PMID 36163116›Full record

ArticleCell death discovery2022

LIGHT deficiency attenuates acute kidney disease development in an in vivo experimental renal ischemia and reperfusion injury model.

Quan-You Zheng, You Li, Shen-Ju Liang, Xi-Ming Chen, Ming Tang, Zheng-Sheng Rao, Gui-Qing Li, Jian-Li Feng, Yu Zhong, Jian Chen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Mitophagy Regulates Kidney Diseases.Kidney diseases (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Quan-You Zheng *Department of Urology, The 958th Hospital, The First Affiliated Hospital, Army Medical University, Chongqing, 400020, China.ORCID http://orcid.org/0000-0003-2476-1421
You Li *Department of Immunology, Army Medical University, Chongqing, 400038, China.
Shen-Ju LiangDepartment of Rheumatism and Immunology, The Third Affiliated Hospital, Army Medical University, Chongqing, 400042, China.
Xi-Ming ChenUrinary Nephropathy Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400065, China.
Ming TangUrinary Nephropathy Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400065, China.
Zheng-Sheng RaoUrinary Nephropathy Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400065, China.
Gui-Qing LiDepartment of Immunology, Army Medical University, Chongqing, 400038, China.
Jian-Li FengDepartment of Urology, The 958th Hospital, The First Affiliated Hospital, Army Medical University, Chongqing, 400020, China.
Yu ZhongDepartment of Urology, The 958th Hospital, The First Affiliated Hospital, Army Medical University, Chongqing, 400020, China.
Jian ChenDepartment of Immunology, Army Medical University, Chongqing, 400038, China.
Gui-Lian XuDepartment of Immunology, Army Medical University, Chongqing, 400038, China. xuguilian2004@163.com.ORCID http://orcid.org/0000-0002-8816-8769
Ke-Qin ZhangDepartment of Nephrology, The First Affiliated Hospital, Army Medical University, Chongqing, 400038, China. zhkq2004@163.com.ORCID http://orcid.org/0000-0001-9342-6374
Army Medical University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemia-reperfusion (I/R), a leading risk factor of acute kidney injury (AKI), is associated with high mortality and risk of progression to chronic kidney disease. However, the molecular mechanism of I/R-AKI remains not fully understood, which hinders its efficient clinical treatment. In this study, we observed that LIGHT deficiency remarkably attenuated I/R-AKI, as evidenced by rescued renal function, ameliorated tubular cell apoptosis, and alleviated inflammatory responses. Consistently, blocking LIGHT signaling with its soluble receptor fusion proteins (HVEM-IgG-Fc or LTβR-IgG-Fc) improved I/R renal dysfunction. RNA-sequencing and corresponding results indicated that LIGHT promoted oxidative stress and inflammation triggered by ischemic injury. Moreover, LIGHT signaling augmented ischemic stress-induced mitochondrial dysfunction characterized by an imbalance in mitochondrial fission and fusion, decreased mtDNA copies, impaired mitophagy, and increased mitochondrial membrane potential (ΔΨm). Mechanistically, LIGHT promoted mitochondrial fission by enhancing Drp1 phosphorylation (Ser616) and its translocation to the mitochondria. In conclusion, these results suggest that LIGHT-HVEM/LTβR signaling is critical for the I/R-AKI pathogenesis and it is further confirmed to be related to the increase in I/R-induced oxidative stress and mitochondria dysfunction, which may be the underlying mechanism of LIGHT signaling-mediated I/R-AKI.

Identifiers

PMID36163116
PMCPMC9512920
OpenAlexW4297222462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.